FDA blocks Lilly, Boehringer's Jardiance from coveted Type 1 diabetes nod

Eli Lilly and Boehringer Ingelheim's SGLT2 med Jardiance has had a tough fight in Type 2 diabetes against competitors from AstraZeneca and Johnson & Johnson. The partners hoped they could take Jardiance into Type 1 under a different brand name to get a leg up, but now those hopes appear dashed.